{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:31:59Z","timestamp":1773225119273,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jdermsci.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:20:57Z","timestamp":1758946857000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular profile of interleukin-17RA blockade by brodalumab in Japanese patients with psoriasis: Results from the ESPRIT study"],"prefix":"10.1016","volume":"120","author":[{"given":"James G.","family":"Krueger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Uchida-Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisaku","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukie","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Beom","family":"Hur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Garcet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Shishido-Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jdermsci.2025.09.005_bib1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2025.09.005_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","article-title":"Highly effective new treatments for psoriasis target the IL-23\/Type 17 t cell autoimmune axis","volume":"68","author":"Kim","year":"2017","journal-title":"Annu. Rev. Med."},{"issue":"5","key":"10.1016\/j.jdermsci.2025.09.005_bib3","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J. immunol."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.09.005_bib4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"13","key":"10.1016\/j.jdermsci.2025.09.005_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC review topic of the week","volume":"77","author":"Garshick","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.jdermsci.2025.09.005_bib6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/exd.14582","article-title":"Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris","volume":"31","author":"Koschitzky","year":"2022","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2025.09.005_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdermsci.2023.01.003","article-title":"Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study","volume":"109","author":"Blauvelt","year":"2023","journal-title":"J. Dermatol. Sci."},{"issue":"5","key":"10.1016\/j.jdermsci.2025.09.005_bib8","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.jaci.2019.01.017","article-title":"Modulation of inflammatory gene transcripts in psoriasis vulgaris: differences between ustekinumab and etanercept","volume":"143","author":"Brodmerkel","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.jdermsci.2025.09.005_bib9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamadermatol.2021.3492","article-title":"Effect of costimulatory blockade with abatacept after ustekinumab withdrawal in patients with moderate to severe plaque psoriasis: the PAUSE randomized clinical trial","volume":"157","author":"Harris","year":"2021","journal-title":"JAMA Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2025.09.005_bib10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis","volume":"145","author":"Tomalin","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.09.005_bib11","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.jaci.2018.11.042","article-title":"Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab","volume":"143","author":"Visvanathan","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"16","key":"10.1016\/j.jdermsci.2025.09.005_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10163640","article-title":"Relationship between psoriasis and prevalence of cardiovascular disease in 88 Japanese patients","volume":"10","author":"Yamazaki","year":"2021","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.jdermsci.2025.09.005_bib13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00109-005-0721-x","article-title":"Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals","volume":"83","author":"Kulski","year":"2005","journal-title":"J. Mol. Med."},{"issue":"5","key":"10.1016\/j.jdermsci.2025.09.005_bib14","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications","volume":"135","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jdermsci.2025.09.005_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jid.2017.08.040","article-title":"Reduction of inflammatory and cardiovascular proteins in the blood of patients with psoriasis: differential responses between tofacitinib and etanercept after 4 weeks of treatment","volume":"138","author":"Kim","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2025.09.005_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2019.01.003","article-title":"Identification of six cardiovascular risk biomarkers in the young population: a promising tool for early prevention","volume":"282","author":"Mart\u00ednez","year":"2019","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jdermsci.2025.09.005_bib17","first-page":"1415","article-title":"Screening genes associated with elevated neutrophil\u2011to\u2011lymphocyte ratio in chronic heart failure","volume":"18","author":"Wan","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"8","key":"10.1016\/j.jdermsci.2025.09.005_bib18","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J. immunol."},{"issue":"2","key":"10.1016\/j.jdermsci.2025.09.005_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/ijd.14217","article-title":"Serum elafin as a potential inflammatory marker in psoriasis","volume":"58","author":"Elgharib","year":"2019","journal-title":"Int. J. Dermatol."},{"issue":"2","key":"10.1016\/j.jdermsci.2025.09.005_bib20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/rheumatology\/keaa405","article-title":"Broad proteomic screen reveals shared serum proteomic signature in patients with psoriatic arthritis and psoriasis without arthritis","volume":"60","author":"Leijten","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jdermsci.2025.09.005_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/ijms23010555","article-title":"IL-17 pathway members as potential biomarkers of effective systemic treatment and cardiovascular disease in patients with Moderate-to-Severe psoriasis","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.09.005_bib22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.bcp.2011.11.003","article-title":"Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium","volume":"83","author":"Alam","year":"2012","journal-title":"Biochem. Pharmacol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181125001781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181125001781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:56:21Z","timestamp":1773150981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181125001781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0923181125001781"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2025.09.005","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular profile of interleukin-17RA blockade by brodalumab in Japanese patients with psoriasis: Results from the ESPRIT study","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}